The activity of cancer procoagulant in cases of uterine leiomyomas

Purpose: It is currently believed that cancer procoagulant (CP), an enzymatic protein, is a product of malignant neoplastic cells. The present study was designed to test whether it is also synthesized by benign neoplastic cells, namely uterine leiomyomas.

Materials and methods: We determined the activity of CP in the blood serum of women with uterine leiomyomas (N = 24), normal women (N = 15), and genital cancer patients (N = 6) by the coagulative method according to Gordon and Benson. Also, the CP activity in 10% tissue homogenates of uterine leiomyomas, normal uterine muscle and tissues of cervical and endometrial carcinoma was determined by the chromogenic method according to Colucci et al.

Results: The mean CP activity in the sera of women with uterine leiomyomas was 181.1 seconds (s) +/- 19.9 s, in healthy women--293.2 s +/- 33.8 s, and in genital cancer patients--78.8 +/- 18.5 s (all differences: p < 0.001). Similarly, in homogenates of uterine leiomyomas the CP activity was 19.6 +/- 3.8 nmoles pNa/ml, in normal uterine muscle it was 13.2 +/- 2.2 nmoles pNa/ml, and in cancerous tissue--28.0 +/- 6.6 nmol pNa/ml (all values being significantly different from each other). There was a strong correlation (r = -0.8122; p < 0.001) between the CP activity in uterine leiomyomas and serum activity, suggesting that the source of the serum CP activity was from the leiomyoma. The coagulation time of 120 to 240 s by the Gordon and Benson method supported the diagnosis of uterine leiomyoma, and a value below 120 s--the suspicion of genital cancer.

Conclusions: Uterine leiomyomas, representing benign genital neoplasia, synthesize CP and are the likely origin of CP activity in blood, as has been described for malignant tumors, but to a lesser degree. There may be a role for CP as a tumor marker of genital neoplasia.

Cancer procoagulant; Clotting system; Uterine leiomyomas

[1] Gordon S.G., Mourad A.M.: "The site of activation of factor X by cancer procoagulant". Blood Coagul. Fihrinolysis, 1991, 2, 735.

[2] Gordon S.G., Chellandurai M.: "Non-tissue factor procoagulants in cancer cells". Cancer Metastasis Rev., 1992, 11, 267.

[3] Gordon S.G., Franks J.J., Lewis BJ.: "Comparison of procoagulant activities in extracts of normal and malignant human tissue". J. Natl. Cancer Inst., 1979, 62, 773.

[4] Gale A.J., Gordon S.G.: "Update on tumor cell procoagulant factors". Acta Haematol., 2001,106, 25.

[5] Gordon S.G.,B enson B.: "Analysis of serum cancer procoagulant activity and its possible use as a tumor marker". Thromb. Res., 1989, 56, 431.

[6] Kozwich D.L., Kramer L.C., Mielicki W.P., Fotopoulos S.S., Gordon S.G.: "Application of cancer procoagulant as an early detection tumor marker". Cancer, 1994, 74, 1367.

[7] Kozuszko B., Skrzydlewska E., Snarska J., Kozlowski M., Zalewski B., Skrzydlewski Z.: "Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer". Folia Histochem. Cytobiol., 2001, 39 (suppl2), 104.

[8] Rucinska M.,S krzydlewski Z.,Z aremba E.,F urman M., Kasacka I.: "Cancer procoagulant (CP) in lung cancer". Roczniki Akad Med. Bialymstoku, 1997, 42, 251.

[9] Mielicki W.P., Tendercnda M., Rutkowski P., Chojnowski K "Activation of blood coagulation and the activity of cancer procoagulant in breast cancer patients". Cancer Lett., 1999, 146, 61.

[10] Szajda S.D., J6zwik M., Wisniewski R., Skrzydlewski Z.: ["The serum activity of cancer procoagulant in cases of uterine and ovarian neoplasia"] (in Polish). Wsp6lczesna Onkologia, 2002, 6, 571.

[11] FIGO: "Changes in gynecologic staging by the International Federation of Gynecology and Obstetrics". Am. J. Obstet. Gynecol., 1990, 162, 610.

[12] Colucci M., Cutatolo L., Donati M.B., Semeraro N.: "Cancer cell procoagulant activity: evaluation by an amidolytic assay". Thromb Res., 1980, 18, 589.

[13] Cicinelli E., Ziegler D.: "New hypothesis. Transvaginal progesterone: evidence for a new functional "portal system" flowing from the vagina to the uterus". Hum. Reprod. Update, 1999, 5, 365.

[14] Duffy M.J.: "Clinical uses of tumor markers: a critical review". Crit. Rev. Clin. Lab. Sci., 2001, 38, 225.

[15] Gordon S.G., Cross B.A.: "A factor X activating cysteine protease from malignant tissue". J. Clin. Invest., 1981, 67, 1665.

[16] Mielicki W.P., Tagawa M., Gordon S.G.: "New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors". Thromb. Haemost., 1994, 71, 456.

[17] Mielicki W.: "Biochemistry of cancer procoagulant". Haemostasis, 2001, 31 (suppl. 1), 8.

[18] Falanga A., Rockies F.R.: "Pathophysiology of the thrombophihc state in the cancer patient". Semin. Thromb. Hemost., 1999, 25, 173.

[19] Fried W., Ward H.P., Hopeman A.R.: "Leiomyoma and erythrocytosis: a tumor producing a factor which increases erythropoietin production. Report of case". Blood, 1968, 31, 813.

[20] Eldor A., Even-Paz Z., Polliack A.: "Erythrocytosis associated with multiple cutaneous leiomyomata: report of a case with demonstration of erythropoietic activity in the tumour". Scand. J. Haematol., 1976, 16, 245.

[21] Naets J.P., Wittek M., Delwiche F., Kram I.: "Polycythaemia and erythropoietin producing uterine fibromyoma". Scand. J. Haematol., 1977, 19, 75.

[22] Kessler C.M., Szymanski L.M., Shamsipour Z., Muesing R.A., Miller VT., LaRosa J.C.: "Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes". Obstet. Gynecol., 1997, 89, 326.

[23] Demirol A., Baykal C., Kirazli S., Ayhan A.: "Effects of hormone replacement on hemostasis in spontaneous menopause" Menopause, 2001, 8, 135.